Drug receptor based

It is amazing to note that complex processes such as drug binding to protein, activation of cells, and observation of syncytial cellular response should apparently so closely follow a model based on these simple concepts. This was not lost on A. J. Clark in his treatise on drug receptor theory The Mode of Action of Drugs on Cells [4] ... 

As noted in Chapter 1, the most simple and theoretically sound model for drug-receptor interaction is the Langmuir adsorption isotherm. Other models, based on receptor behavior (see Chapter 3), are available. One feature of all of these models (with the exception of some instances of the... 

G6PD deficiency is discussed in Chapters 20 and 52 and malignant hyperthermia in Chapter 49. At least one gene other than that encoding the ryanodine receptor is involved in certain cases of malignant hypertension. Many other examples of drug reactions based on polymorphism or mutation are available. 

Analytical models of the heart are a reality. They are based on detailed descriptions of cardiac tissue architecture and anatomy, including the coronary vasculature. In sihco cardiac tissues possess realistic passive mechanical properties, and both electrical and mechanical activity can be simulated with high accuracy. Descriptions of key components of cellular metabolism have been introduced, as have models of drug-receptor interactions. 

For a detailed description of spectral map analysis (SMA), the reader is referred to Section 31.3.5. The method has been designed specifically for the study of drug-receptor interactions [37,44]. The interpretation of the resulting spectral map is different from that of the usual principal components biplot. The former is symmetric with respect to rows and columns, while the latter is not. In particular, the spectral map displays interactions between compounds and receptors. It shows which compounds are most specific for which receptors (or tests) and vice versa. This property will be illustrated by means of an analysis of data reporting on the binding affinities of various opioid analgesics to various opioid receptors [45,46]. In contrast with the previous approach, this application is not based on extra-thermodynamic properties, but is derived entirely from biological activity spectra. 

Receptor-Based Drug Design, edited by Paul Left... 

There are a variety of structural classes of compounds that are active against each phosphodiesterase, and evidence suggests that selective inhibitors of PDEs can be identified. The structural diversity of PDE inhibitors provides a multitude of opportunities for development of compounds with drug-like properties. Furthermore, phosphodiesterase inhibition, which avoids direct interaction of a compound with a cell surface or nuclear receptor, may circumvent some of the target selectivity issues that can complicate receptor-based therapeutic approaches. As noted above, the specific subcellular distribution of phosphodiesterase enzymes is a key feature of their ability to modulate intracellular signaling pathways. This localization of the enzyme may minimize non-specific target... 

To study drug-receptor/enzyme interaction, it is not always convenient or appropriate to use a living system of the target receptor. Instead, biochemical assays can be devised to mimic the target. Very often, the assays use multicolor luminescence or fluorescence-based reagents. In this way, the reaction path can be followed in space and time to enable quantitative evaluation of the reaction. 

Leff P, ed. Receptor-Based Drug Design, Drugs and the Pharmaceutical Sciences, Volume 89, Marcel Dekker, New York, 1998. 

Oprea, T.l. and Marshall, G.R. Receptor-based prediction of binding affinities. In 3D-QSAR in Drug Design, Kubinyi, H., Folkers, G., and Martin, Y.C. (Eds.). Kluwer/ESCOM, Dordrecht, NL, 1998, 35-61. 

Perez, C., Pastor, M., Ortiz, A.R., and Gago, F. Comparative binding energy analysis of HIV-1 protease inhibitors incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. /. Med. Chem. 1998, 41, 836-852. 

Table 14.2. Organ and tissue selective distribution of potential drug carriers based on receptor recognizing principles a few examples.

In the last chapter receptor-based diagnostic radiopharmaceuticals are reviewed including considerations on drug design, on receptors, and on receptor imaging with the objective of modifying the pharmacokinetics of these agents. 

The development of the benzodiazepine class of drugs for the treatment of a variety of neurological indications has proven to be an outstanting success story in the field of chemotherapy. However, these compounds often produce undesirable side effects when used as anti-anxiety or hypnotic agents. These side effects include sedation, physical dependence, amnesia, muscle relaxation, and ethanol potentiation. The development of a benzodiazepine receptor-based anxiolytic agent devoid of these side effects would constitute a major advance in the field and has been the focus of significant research efforts [284]. 

A variety of responses in the body to different adrenergic drugs are based on their relative selectivity when binding with various receptors, which are exclusively found in and unevenly distributed in effector structures (heart, cardiovascular system, lungs, brain, peripheral nervous system, etc.). 

---